Clinical Trial Management - software & AI news

Daily news on software, AI, and companies shaping clinical trial management.

Showing 118 results
A minimalist illustration of a clipboard with a checkmark, symbolizing clinical processes.

Jun 3, 2026

Medable Launches Agentic Accelerator Program to Help Life Sciences Companies Deploy Agentic AI Across Clinical Lifecycle

Medable has introduced its Agentic Accelerator Program aimed at enhancing clinical development through agentic AI technology.The new program is designed to assist life sciences companies, including sponsors and contract research organizations (CROs), in effectively integrating agentic AI into their clinical processes. It offers comprehensive support that encompasses onboarding, governance, and change management, ensuring that organizations can derive value from AI from the outset. Notably, despi
A flat illustration of imaging film and data analysis graph

Jun 2, 2026

Medidata Unveils AI-Powered Imaging Solution to Accelerate Clinical Trial Analysis

Medidata has introduced an advanced AI-driven imaging solution aimed at enhancing the efficiency and accuracy of clinical trial data analysis, particularly in oncology.The new offering, unveiled at the ASCO 2026 Annual Meeting, is part of Medidata's Data Experience platform and is designed to tackle common imaging-related challenges in clinical trials. By integrating artificial intelligence into imaging workflows, the solution aims to significantly reduce delays in data processing and improve ov
A minimalist representation of a drug capsule and stomach silhouette in dark colors.

Jun 2, 2026

Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis

Dr. Falk Pharma and Renexxion are advancing naronapride into late-stage development, following promising Phase 2b results for treating gastroparesis.Renexxion, a biopharmaceutical firm focused on gastrointestinal disorders, is collaborating with Dr. Falk Pharma to progress naronapride into pivotal Phase 3 studies aimed at addressing gastroparesis. This follows encouraging outcomes from the MOVE-IT trial involving 328 patients, which demonstrated naronapride's potential to meet significant unmet
Silhouette of a stack of papers representing clinical trial data

Jun 1, 2026

Pharma’s Trial Problem: Outdated Systems, Broken Data, and the Coming AI Reset

The pharmaceutical industry is grappling with significant challenges in clinical trials, where outdated systems and inefficient data management are hindering innovation. Despite advancements in science, clinical trials consume a staggering 60-70% of R&D budgets, with inefficiencies leading to prolonged timelines and escalating costs.The core issue lies in the structural limitations of trial data organization, which has not evolved alongside modern methodologies. Traditional clinical trial models
A stack of clinical trial documents on a conference table with a whiteboard in the background.

May 29, 2026

Half of clinical trial professionals cite trust and regulatory gaps as barrier to AI adoption, Pistoia Alliance poll finds

A recent poll conducted by the Pistoia Alliance highlights significant barriers to AI adoption in clinical trials, with trust and regulatory uncertainty being the primary concerns for 50% of respondents. This survey was part of the Clinical Trials Technology Congress in London, where discussions centered on how regulators are prepared to collaborate with pharmaceutical companies to ensure the safe and compliant integration of AI technologies.At the Congress, regulators from various agencies expr
A minimalist illustration of a clinical trial participant's arm with a blood drop, set against a dark background.

May 29, 2026

AI’s next pharma challenge: tackling costly and risky clinical trials

AI is poised to revolutionize the clinical trial landscape, addressing long-standing inefficiencies and high costs associated with drug testing.Pharmaceutical companies have long faced significant challenges in clinical trials, with the average drug development process taking over a decade and costing between $1-2 billion. A staggering 90% of drugs fail during human testing, leading to wasted resources and delayed patient access. However, advancements in artificial intelligence (AI) are emerging
A flat design of a clinical trial protocol document with a checkmark

May 21, 2026

Avenio AI Names Dr. Cyrus Ghobadi Board Advisor as Artiko Pharma

Avenio AI has appointed Dr. Cyrus Ghobadi as a Board Advisor, coinciding with Artiko Pharma's adoption of Avenio's Intelligent Protocol Hub to streamline clinical development processes.Dr. Ghobadi, a seasoned expert with extensive experience at major pharmaceutical companies, will leverage Avenio AI's technology to enhance protocol authoring and reduce timelines from IND submission to first-patient-in. His dual perspective as both a physician and a clinical developer positions him uniquely to ad
Minimalist illustration of a cloud symbolizing digital platforms in life sciences

May 20, 2026

Dassault Systèmes stock (FR0014003TT8): software group lifts 2025 outlook after solid Q1

Dassault Systèmes has updated its 2025 financial outlook following strong first-quarter results, highlighting robust demand for its cloud platform and life sciences solutions.The company reported increased revenue and operating income, prompting an upward revision of its targets for 2025. This growth is largely attributed to the success of its 3DEXPERIENCE cloud platform and life sciences software, which have attracted interest from technology-focused investors. The diversification into life sci
A syringe and vial of biosimilar in a clinical trial setting

May 19, 2026

How IQVIA’s Expanded AI Biosimilar Partnership with Kexing Biopharm Will Impact IQVIA Holdings (IQV) Investors

Kexing Biopharm's expanded partnership with IQVIA marks a significant step in the biosimilar landscape, leveraging AI to enhance clinical trial efficiency and commercialization strategies. This collaboration aims to streamline the development process for multiple biosimilar products globally, showcasing IQVIA's commitment to integrating AI technologies into clinical workflows.This partnership emphasizes IQVIA's strategic focus on utilizing AI to meet the demands of biosimilar developers, who are
Minimalist illustration of a pill representing pharmaceutical collaboration

May 15, 2026

Bristol-Myers Squibb stock (US1078421011): new mega-deal and AI push keep pipeline in focus

Bristol-Myers Squibb is making significant strides in its pipeline and technological capabilities, highlighted by a massive partnership with Hengrui Pharma and an expansion of its AI-driven clinical trial collaboration with Tempus.The pharmaceutical giant has entered into a global collaboration and licensing agreement with China's Hengrui Pharma, valued at up to $15.2 billion. This deal will focus on the joint development of 13 early-stage assets in oncology, hematology, and immunology, allowing
Lung tissue sample on a lab bench with a CT scan machine in the background.

May 12, 2026

Boehringer, Brainomix plan new trial of lung fibrosis AI

Boehringer Ingelheim and Brainomix are expanding their collaboration on an AI tool aimed at diagnosing interstitial lung diseases (ILDs) with a new prospective clinical trial.The partnership, which began in 2024, focuses on utilizing Brainomix's e-Lung software to enhance the diagnosis of conditions like progressive pulmonary fibrosis (PPF). The findings from a retrospective study, REVISE-PPF, will be presented at an upcoming conference, showcasing how e-Lung analyzed historical CT scans to iden
Map pin symbolizing community practices in cancer treatment

May 8, 2026

Caris Life Sciences (Nasdaq:CAI) - Stock Analysis

Caris Life Sciences is addressing the significant access gap in cancer clinical trials with its innovative Right-In-Time (RIT) solution, aimed at expanding the reach of precision oncology to community practices across the U.S.The urgency to bridge the geographic divide in cancer trial access is underscored by research indicating that 70% of U.S. counties lack active cancer treatment trials. This limitation affects nearly 20% of older Americans, who do not have local options for investigational t